Aptose Biosciences (APS) Stock Statistics & Valuation Metrics

Aptose Biosciences has a market cap or net worth of C$6.09M. The enterprise value is C$3.62M.

Aptose Biosciences has 2,552,429 shares outstanding. The number of shares has decreased by -2.65% in one year.

Aptose Biosciences’s return on equity (ROE) is 0.96 and return on invested capital (ROIC) is -2803.30%.

The current PE Ratio of Aptose Biosciences is ―. Aptose Biosciences’s PEG ratio is 0.00.

In the last 12 months, Aptose Biosciences had revenue of 0.00 and earned -25.91M in profits. Earnings per share was -10.59.

In the last 12 months, operating cash flow was -22.08M and capital expenditures 0.00, giving a free cash flow of -22.08M billion.

Aptose Biosciences pays an annual dividend of ―, resulting in a dividend yield of ―

Aptose Biosciences upcoming earnings date is May 11, 2026, TBA (Confirmed).

Aptose Biosciences as a current ratio of ―, with Debt / Equity ratio of -0.71%

In the past 12 months, Aptose Biosciences has paid 0.00 in taxes.

Aptose Biosciences EV to EBITDA ratio is -1.12, with an EV/FCF ratio of -1.24.

Aptose Biosciences has C$4.09M in cash and marketable securities with C$28.01M in debt, giving a net cash position of -C$23.93M billion.

Gross margin is 0.00%, with operating margin of ―, and net profit margin of ―.

The average price target for Aptose Biosciences is ―, which is 11.43% higher than the current price. The consensus rating is ―